Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

BUY Dishman Pharma - Better traction expected from CRAMS and disinfectants: AnandRathi Institutional Research

Posted On: 2016-09-25 09:04:08

Dishman Pharma - Better traction expected from CRAMS and disinfectants; Buy with a target price of Rs 226

For a better understanding of the business and the outlook for the next 2-3 years, we met the Dishman management recently. In addition to margin improvement, which has been the case for FY16 (and expected in FY17), revenue growth would be driven by growth in its CRAMS base business, additional business on the commercialization of potential molecules and the further business in disinfectants from FY18. We introduce FY19 estimates, maintaining our Rs. 226 target and Buy rating due to 33% potential.

Phase-III molecules: In its CRAMS business, Dishman has about 13 molecules in phase-III of clinical trials. Of these, about 6-7 are in oncology. The commercialization of 2-3 molecules can be expected in 18-24 months, and would be revenue drivers in CRAMS.

More outsourcing by J&J in disinfectants: There is shift of manufacturing of ~20 products by J&J from its own base to Dishman's facility. This is expected to raise the revenue base of Rs. 100m to Rs. 1bn over next 2-3 years. This outsourcing would start from FY18.

More Eprosartan business through higher volumes: Dishman guided to more outsourcing of Eprosartan by Solvay from Dishman's facility, which would begin from FY18. This would result in ~20% yoy growth in this business for Dishman.

Introducing FY19e. Our FY19 estimates are: sales Rs. 20.5bn, PAT Rs. 3.2bn, factoring in respectively 12% and 24% yoy growth, based on more business from CRAMS and disinfectants.

Valuation. At the CMP of Rs. 175, the stock trades at 13x FY17e EPS of Rs. 13.5 and 10.8x FY18e EPS of Rs. 16.1. We maintain a Buy, with a target of Rs. 226 based on 14x FY18e earnings. Risks. Currency fluctuations and delay in approvals.

Shares of DISHMAN PHARMACEUTICALS & CHEMICALS LTD. was last trading in BSE at Rs.210.05 as compared to the previous close of Rs. 217.8. The total number of shares traded during the day was 565833 in over 8274 trades.

The stock hit an intraday high of Rs. 227.9 and intraday low of 208.2. The net turnover during the day was Rs. 123652429.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Supreme Industries - Visit Note - Plastic Industry Juggernaut - Nirmal Bang
Crompton Greaves Consumer Electricals - Initiating Coverage - Rechristened For An Electrifying Future - Nirmal Bang
AU Small Finance Bank - IPO Update - Unique Positioning - Nirmal Bang
AU Small Finance Bank Ltd - IPO Note - Angel Broking
Company Visit Note: Maithan Alloys Ltd. (MAL) - NOT RATED - Kotak
Economy/Strategy: GST: Godot has arrived - Kotak
The Pitch Report: Karnataka Bank Ltd - BUY - TP Rs.220 - Kotak
Company Update: Voltas Ltd - ACCUMULATE - TP Rs.500 - Kotak
Technology: Accenture-tightens revenue growth guidance band - Kotak
Metals & Mining (Attractive): India Steel-on a recovery path - Kotak
Nasscom guides for 7-8% growth, lower than 8.6% in c/c of FY2017 - Kotak
Technology: Nasscom guidance - Decelerating growth trend continues - Kotak
Company Visit Note: Huhtamaki PPL Ltd (HPPL) - NOT RATED - Kotak
Company Update: Shipping Corporation of India - BUY - TP Rs.110 - Kotak
IT Industry to grow at 8-9% in FY2018; Nasscom: Angel Broking
Lupin - USFDA update: Angel Broking
Company Visit Note: The Mandhana Retail Ventures Ltd - NOT RATED - Kotak
Banks : Offers protection in adverse conditions - A deeper study into Pradhan Mantri Fasal Bima Yojana - Agriculture Insurance scheme - Kotak
Energy - downstream PSUs: When the tide turns - Kotak
Company Update: Mahindra and Mahindra (M&M) - BUY - TP Rs.1565 - Kotak
Maharashtra government removes cap on taxi / auto licenses: Angel Broking
IPCA Labs - USFDA update: Angel Broking
Company Update: Gujarat State Petronet Ltd (GSPL) - ACCUMULATE - TP Rs.182 - Kotak
Management Meet Update - Zensar Technologies - CSEC Research
Company Update: VRL Logistics Ltd - BUY - TP Rs.375 - Kotak
Strategy: The impossible trinity of farm income - Kotak
Banks : Private banks accelerate gains on CASA : Deeper study into deposit profile of banks for FY2016 - Kotak
Company Update: Blue Star - ACCUMULATE - TP Rs.684 - Kotak
Banking : RBI gets into action - Kotak
Dr Reddy's - EIR for its Miryalaguda API plant: Angel Broking
Eris Lifesciences Limited - IPO Note - Angel Broking
Banks: Maharashtra announces farm loan waiver - Kotak
Company Update: Petronet LNG - ACCUMULATE - TP Rs.462 - Kotak
Company Update: Mirza International - REDUCE - TP Rs.161 - Kotak
Fiem Industries - BUY - TP Rs.1,254 - Kotak
Insurance: ICICI Prudential Life boosts industry growth - Kotak
Tejas Networks - A destination for high speed technology: Angel Broking
Hindalo Industries - Result Update - Strong show becoming a routine, maintain Buy - Centrum
Star Cement - Result Update - Profitability rebounds on better pricing, cost reduction - Centrum
FIEM Industries - Result Update - Negatives priced in, Well poised to gain in the long term - Centrum
Birla Corporation - Strong Q4 FY17; acquisition reporting strong numbers; Buy - Anand Rathi
Escorts Ltd - Ready for next leg - PhillipCapital
Earnings Update - Talwalkars Better Value Fitness (TBVF IN) - Results on expected line - CSEC Research
Result Update: Adani Port and Special Economic Zone (APZ) - BUY - TP Rs.425 - Kotak
Telecom: Two quarters of Jio - assessing the impact - Kotak
Earnings Update - Balkrishna Industries (BIL IN) - Strong volume growth continues - CSEC Research
Earnings Update - Kaveri Seeds Ltd(KSCL IN) - Muted performance - CSEC Research
Earnings Update - TTK Prestige (TTKPT IN) - Results in-line with expectation - CSEC Research
Earnings Update - Berger Paints (BRGR IN) - Results in-line with expectation - CSEC Research
Mayur Uniquoters - Footwear segment dragged performance; Maintain Hold - Awanish Chandra and Vikas Rajpal - Centrum


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017